Abstract 2973: NI-3201,a PD-L1xCD28 bispecific antibody for immune checkpoint-dependent CD28 co-stimulation

作者
Sara Majocchi,Pauline Lloveras,Coline Burnet-Merlin,Lise Nouveau,Pauline Malinge,Valéry Moine,Giovanni Magistrelli,Limin Shang,Nicolas Fischer,Krzysztof Masternak,Walter G. Ferlin
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (7_Supplement): 2973-2973
标识
DOI:10.1158/1538-7445.am2023-2973
摘要

Abstract CD28 agonism on T cells delivers a critical second signal alongside TCR ligation for complete T cell activation. In the tumor microenvironment (TME), signal 2 can be provided by bispecific antibodies (bsAbs) targeting CD28 and a tumor associated antigen (TAA), enabling CD28 clustering on T cells in a TAA-dependent manner. The inhibitory PD-L1/PD-1 axis is described to repress T cell activation by directly inhibiting CD28 driven costimulation, affecting mostly activated and/or exhausted T cells. Preclinical studies have shown the benefit of combining blocking anti-PD-1/-L1 antibodies and costimulatory CD28 bsAbs for the treatment of solid tumors. We reasoned that the effect of such a combination could be integrated into a single molecule, by associating a blocking anti-PD-L1 antibody arm with an agonist anti-CD28 antibody arm. To this end, a PD-L1xCD28 bsAb (NI-3201) was generated on the κλ body platform to block the PD-L1/PD-1 immune checkpoint, hence release the brake on CD28 signaling and provide signal 2 when co-ligating PD-L1+ tumor and immune cells (e.g., antigen-presenting cells). The capacity of NI-3201 to provide signal 2 to T cells following co-engagement of PD-L1 on tumor or immune cells was assessed in a variety of assays and models. Using a sensitive reporter cell bioassay, NI-3201 was shown to efficiently block the PD-L1/PD-1 axis. The pharmacological activity of NI-3201 was then assessed through in vitro assays of cancer cell lines co-cultured with human peripheral blood mononuclear cells (PBMCs). NI-3201 synergized with CD3 bsAbs to enhance activation and proliferation of both CD4 and CD8 T cells, ultimately leading to strengthened T cell-dependent cellular cytotoxicity (TDCC) against PD-L1-positive cancer cell lines. In immunocompetent huCD28-transgenic mice engrafted with huPD-L1-expressing murine colon adenocarcinoma MC38 cells, NI-3201 displayed superior single-agent activity as compared to the anti-PD-L1 antibody Atezolizumab, with tumor regression being observed in all treated mice. At study termination, most of the NI-3201-treated mice rejected MC38-huPD-L1 tumors. All surviving mice rechallenged with wild type MC38 cells rejected the tumors, thus demonstrating a durable anti-tumor immunological memory response induced by NI-3201. Finally, as the anti-PD-L1 arm of NI-3201 is cross-reactive to mouse PD-L1, it was noteworthy that NI-3201-treated huCD28-transgenic mice displayed no clinical signs of toxicity. NI-3201 has demonstrated potent activity in a plethora of assays and single agent anti-tumor in vivo activity superior to a clinically approved PD-L1 benchmark. The mechanism of action of NI-3201 and the data presented herein support the use of this molecule as a universal combination partner for CD3-bispecifics. Pre-clinical development of NI-3201 is ongoing, with pharmacokinetic and tolerability studies in non-human primates planned for early 2023. Citation Format: Sara Majocchi, Pauline Lloveras, Coline Burnet-Merlin, Lise Nouveau, Pauline Malinge, Valery Moine, Giovanni Magistrelli, Limin Shang, Nicolas Fischer, Krzysztof Masternak, Walter Ferlin. NI-3201,a PD-L1xCD28 bispecific antibody for immune checkpoint-dependent CD28 co-stimulation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2973.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
675675发布了新的文献求助10
1秒前
汉堡包的应助被小艾同学采纳,获得10
1秒前
2秒前
5秒前
11NING完成签到,获得积分10
5秒前
5秒前
SCI完成签到,获得积分10
6秒前
Koi发布了新的文献求助10
6秒前
禹hs完成签到,获得积分10
9秒前
吱ing完成签到 ,获得积分10
10秒前
ding的应助被bbb采纳,获得10
10秒前
SCI发布了新的文献求助10
10秒前
ZeSheng完成签到,获得积分10
11秒前
12秒前
12秒前
12秒前
眠龙完成签到 ,获得积分10
13秒前
猪猪侠完成签到,获得积分10
14秒前
14秒前
14秒前
英俊的铭的应助被xxx采纳,获得10
15秒前
水煮电吹风的应助被叶95采纳,获得10
15秒前
ylfs完成签到,获得积分10
15秒前
16秒前
bobo完成签到,获得积分10
17秒前
小艾同学发布了新的文献求助10
17秒前
see发布了新的文献求助10
18秒前
在水一方的应助被LILILILI采纳,获得30
19秒前
嘤嘤嘤完成签到,获得积分10
19秒前
19秒前
999完成签到,获得积分10
19秒前
123完成签到 ,获得积分10
20秒前
香蕉觅云的应助被祥子的骆驼采纳,获得10
21秒前
。。。完成签到,获得积分0
23秒前
自然思烟完成签到,获得积分10
24秒前
bbb发布了新的文献求助10
26秒前
冷酷以山发布了新的文献求助10
26秒前
anders完成签到 ,获得积分10
28秒前
进化又不带我完成签到 ,获得积分10
28秒前
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568